14 ms·
Pfizer and BioNTech Conclude Phase 3 Study of Covid-19 Vaccine Candidate
- mxschmitt 6y agogreat to see the progress there
- tinus_hn 6y agoSo the distribution and cooling problems are resolved and safety is proven. I wonder what’s the next excuse for delays and FUD.
- flaque 6y agoDelays? We’re going from proof of efficacy to roll out within a few weeks. This is insanely quick.
- deleted 6y ago[deleted]
- virtuallynathan 6y ago41,135 Total enrolled ~20,567 in each arm 162/20,567 cases in the placebo arm (~0.79%) 8/20,567 cases in the vaccine arm (~0.04%) Absolute risk reduction of ~0.75% (over the time period of the study, which is difficult to tell). Number-needed-to-Treat (NNT): 134 vaccinations to prevent 1 symptomatic case over the study duration. Keep in mind, this is over some time period. Annualized, these numbers would almost certainly increase. We don’t know how many days/weeks/months it took to reach 162 / 8 cases respectively (something between ~5-6 months and ~5 days)
- arijun 6y agoCan you help interpret those numbers? Are they good?
- ComputerGuru 6y agoReally, it just means a) it works, b) the study should go on longer to get more significant results.
- timerol 6y agoHow much longer? There is significant benefit to rolling out massive amounts of vaccine immediately. I know that any scientist worth their salt will almost always claim that more study is warranted. But we're playing against a clock measured in human lives right now
- henrikschroder 6y agoAnd if this vaccine doesn't work or has nasty side effects, or even ends up killing people, most people will be very reluctant to take it, or any of the next better vaccines, and that would cause even more deaths. It's a hard problem, and even though the clock is ticking, we also need to get it right the first time.
- robrenaud 6y agoThat relative risk reduction is very signficant, not just statistically signficant, it is very practically signficant too.
- colinmhayes 6y agoSure, but the sample of confirmed positives is so small that it might not include some important subgroups. If only 1 at risk person in the placebo tested positive, and 0 in the vaccinated group did we haven't learned much.
- chadash 6y agoThe relevant piece for most people to know is that based on data from a short time period, people were 20x less likely to get symptomatic COVID if they get the vaccine. The exact number will probably change a bit as more time goes by and more data comes in, but 20x is the ballpark. Things we still don't know: - Does the vaccine also stop you from contracting the virus asymptomatically and spreading it? People enrolled in the trial were only told to get tested if they showed symptoms. - How long does the immunity from the vaccine last? We won't know this for some time.
- acqq 6y agoThe study enrolled more, but slowly increased the number of vaccinated since the start (which was initially, I'd expect, 0) -- the second dose was still not received by all enrolled as of November 13: "The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020." So there is no single date one can reasonably use 41,135 or ~20,567 for the efficacy calculations. As the observations continue (expected up to 2 years) there could be much more useful data there. I also guess the people who haven't received both doses but got sick before are separately counted. The only useful numbers at the moment we have are 8 and 162 (and 1 and 9 for the severe cases). And that we can assume that from all thousands vaccinated these 170 in total got sick by chance, and that the thousands were carefully enough selected to represent bigger population, and using that we can expect that the efficacy won't too dramatically change as more data come in, the same way as the polls can use smaller samples to conclude something about bigger population, if the sampling is careful enough. But some changes are expected. It appears it's still too early to know if those who are vaccinated could protect those who aren't, or if the vaccine protects only those who received it (1) -- but anyway we know that still not all of those who will be vaccinated will be protected from having a severe case: there was up to now one severe case in the vaccinated group, versus 9 severe cases in the placebo group, 11%. --------- 1) https://www.medscape.com/viewarticle/941030 https://www.medscape.com/viewarticle/941030 "In an ideal world, a vaccine would prevent infection entirely and, it follows, also prevent disease and severe disease. But this may be hard to achieve for a respiratory virus vaccine. Animal challenge data suggest that vaccinated animals may still be infected even if they don't experience symptoms. A vaccine that is able to reduce the severity of disease, even if it cannot prevent infection entirely, would obviously still have enormous public health value. Therefore, this is what trials target as their primary aim."
- acqq 6y agoMaybe a better link: https://www.medscape.com/viewarticle/941030?src=soc_tw_201118_mscpedt_news_mdscp_vaccine&faf=1 https://www.medscape.com/viewarticle/941030?src=soc_tw_20111...
- tgb 6y agoIs NNT a good number to use when evaluating effectiveness of vaccines during a pandemic? It'll change substantially over time as the virus waxes and wanes and from location to location. So it won't be comparable across different vaccines. Moreover, the fact that cases create more cases means that preventing 1 case could prevent other future ones.
- virtuallynathan 6y agoI would agree, it probably not a good metric. Just providing some standard numbers for treatments. Keep in mind the definition of a case here is having symptoms, so we don’t know if the vaccine prevents lightly symptomatic or asymptomatic cases, which may or may not result in transmission.
- jrumbut 6y agoI've seen this NNT argument a few places now, and no it doesn't make any sense because most of us will be living in a society for years and years to come so if we resume normal life at some point and it's out there we all will be exposed at some point. Its current prevalence is irrelevant because if we live how we want to live it will be everywhere (assuming no vaccine).
- chadash 6y agoKey words here are "over the study duration" and "over the time period of the study". The study started in late July, so it's been about 4 months. The data that they examine probably lags a bit too and in the intervening period, cases have gone up significantly. Over the course of a longer period of time and with cases on the rise as they are now, I'd expect the risk reduction to be much higher. Edit: Also, these numbers are somewhat skewed by the fact that not all 40k people got the vaccine/placebo at once, but over a period of time.
- cm2187 6y agoIs it cases or symptomatic cases? I presume they were testing their sample regularly. Preventing symptoms would be a great outcome anyway, but it’s not the same as preventing cases.
- chadash 6y agoActually, they are not. They only advise participants to get tested if they show symptoms. So it's possible that a bunch of people on the vaccine are getting asymptomatic cases.
- marricks 6y agoWhere did you get that info? I didn’t read it in the release. That’s not good though... really could but a kink in establishing herd immunity until everyone is actually vaccinated.
- chadash 6y agoPfizer released the study design, available at https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591.... It's a long document, but it's in there.
- marricks 6y agoThank you!
- coldpie 6y agoMy wife is in a different vaccine trial. For her they do a test monthly. They also do a blood draw where I would guess they are checking for antibodies, but I don't know. In addition, she reports in every single day with an app for symptom reporting.
- virtuallynathan 6y ago
- rich_sasha 6y agoI guess you're saying - that's a lot of vaccines needed to prevent a very small number of cases - right? But presumably incidence is low because of safety restrictions (lockdowns, masks etc.) which are untenable long-term. Whereas if we can vaccinate O(everyone), we can, maybe, stop the restrictions?
- maxerickson 6y agoThey are going to charge the US ~$40. So $800,000 to prevent 150 cases. That's incredibly cheap, and doesn't factor in an increase of social activities.
- trebligdivad 6y agoif it's targeted at the elderly/at risk (at first?), the reduction in hospitalisation should be higher; and I'd think that would pay back pretty quickly.
- maxerickson 6y agoYes, it's likely a net reduction in spending, and then on top of that a bunch of harm and death is prevented. Super cheap.
- acqq 6y agoAlready answered two days ago: https://news.ycombinator.com/item?id=25111284 https://news.ycombinator.com/item?id=25111284 In short, we still don't know which measures would have to be kept even when a lot of people are vaccinated. It will be much better known in some time, but it's still not known at this moment. It depends on sterile immunizing properties of the vaccine, which are still unknown. Edit: re the Moderna protocol mentioned in sanxiyn's comment below: even if they will measure sterilizing immunity (as one of their "Secondary" objectives), as far as I know, they still haven't published something on that topic (1) From them we still have only data on the level comparable to those from Pfizer/BioNTech: 90 cases in placebo, 5 in vaccinated, 11 severe cases, all in placebo group. Where "cases" could simply be defined "those who were recognized of having Covid-19" (as the illness). (Also see my other comment here for more general references about the primary objectives of all Phase 3 trials). Here's what Moderna only writes about their secondary objectives in the only release: "Key secondary endpoints include prevention of severe COVID-19 disease and prevention of infection by SARS-CoV-2. The trial will continue to accrue additional data relevant to safety and efficacy even after an EUA is submitted." Meaning, eventually, we should be able to know more. I didn't know that Pfizer doesn't even have that kind analysis written in their protocol, thanks. I'd hope they can add that in some later phase. 1) https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy https://investors.modernatx.com/news-releases/news-release-d...
- y7 6y agoWhy should we care about the absolute risk reduction rather than the 20x relative risk reduction (i.e. "95% effectivity")? The idea of these fixed-term RCTs is that the numbers generalize to larger periods of time, right?
- virtuallynathan 6y agoI’m not sure what you mean by fixed-term. In this case, the Interim analysis was run once 170 cases occurred across both arms combined.
- mmarvick 6y agoWhat the poster means is that going from 0.79% to 0.04% means that 0.75% were prevented from getting it due to the vaccine. You go from 79 per 10000 to 4 per 10000, meaning you saved 75 per 10000. But preventing 0.75% of the population from getting it out of the 0.79% who got it implies 94.9% (0.0075/0.0079) of those who _would_ have gotten it were prevented from getting it. That's the relative ratio. I agree with the poster that the relative number seems more interesting. There are lots of things going on right now (masks, social distancing, etc.) to prevent people from getting COVID. The fact that only 0.79% of the placebo group got it implies a lot about _other_ mitigation factors, and puts a limiting force on how many can be saved by the vaccine (a number less than or equal to 0.79%). Like OP, I wonder if there's any case where the -0.75% number is interesting in and of itself. In fact, if we weren't social distancing, presumably the prevalence of COVID would be much higher and thus the absolute ratio of people prevented from getting COVID would be higher too. The 95% effectiveness number should (theoretically) be the same no matter what other measures you're taking. It would reduce 0.79% of population from getting it to 0.04% getting it, and would reduce 10% of the population from getting it to 0.5% of the population getting it. I'm totally ignoring that lots of people getting the vaccine will lead to less people getting sick and less people spreading it (herd immunity), but you get the point.
- Izkata 6y agoWith absolute numbers of 162 and 8, 94.9% would have an error range of somewhere around 10%, right? So the actual percent would be somewhere in the range of 85-97%? (No actual math done here, I'm ballparking it based on looking at error ranges with sample size 100 at work; my main point is that I don't think the ~20k enrolled in each group affects this particular error range, so even though "94.9%" is stated precisely the actual data isn't nearly so precise)
- tsimionescu 6y agoI'm curious, is there any information on the confidence interval for this 95% number? Intuitively, I would expect the confidence to be pretty low - after all, if tomorrow 2 more people in the vaccine group happen to get sick, the relative risk reduction will go from 20x to 15x. Is there anything wrong with this reasoning?
- Karrot_Kream 6y agoNo, you bring up a great question. This kind of vaccine trial is not designed to provide that information, unfortunately. The goal of this study is to show that the vaccine is at least 30% effective (defined by Vaccine Efficacy (VE) in the Pfizer protocol), with a soft goal of hitting a VE of 50%. We don't know anything about what the total population of _possible_ infections in either arm would be. That said, if we assume that there are in total 170 cases (which is true at this point in time but will change), and that there are 162 cases in the control group and 8 cases in the vaccine group, we can construct a posterior of the VE. Here's an older posterior (done with data from the press releases in the first IA a few days ago) http://blog.fellstat.com/?p=468 http://blog.fellstat.com/?p=468 that graphs this posterior. There is some uncertainty, but as you can see results are still promising. That said we just don't know how case counts will change, and while it will be fascinating to watch the results change over time, these sorts of tests are just about getting enough data to mark a vaccine as effective, not about trying to extrapolate any larger effect.
- ellisv 6y agoBased on publicly available numbers, the 95% Bayesian credible interval is roughly 90.5% to 97.6%.
- ppf 6y agoI hope this isn't a silly question - do we know that the placebo group represented half of the total enrolled? The Pfizer press release is very short on details.
- sanxiyn 6y agoYes we do. Pfizer's trial protocol specifies 1:1 randomization. (Google "C4591001 protocol" to get it.)
- nip180 6y agoGiven exponential growth of the virus, and the very large changes to society made to avoid virus population growth I think the NNT isn’t an effective measurement tool. Clearly the value of the vaccine depends heavily on where/when you are. Additionally, if the virus has an R greater than 1, preventing one person from being infected has a larger impact on total infected population.
- sanxiyn 6y agoThat's the point. Pfizer's trial does not evaluate reduction of R or "preventing one person from being infected". It would have been better if it did, but it does not. NNT is a natural way to measure the result of this trial since the result is about prevention of disease, NOT prevention of infection.
- klmadfejno 6y agoThe Moderna trial had a control group infection rate of 0.6% vs. Pfizer's 0.79%. It doesn't really change the story, but if we are going to split hairs over effectiveness ratings, I wonder how sensitive are they to random variance in the control group outcomes, assuming both drugs are exactly the same (they're not), and both tested populations are exactly the same (they're not).
- cperciva 6y agoThis is a vaccine against a communicable disease. The NNT is almost certainly much lower, since preventing the 154 cases among vaccinated patients would almost certainly prevent cases among their contacts.
- acqq 6y agoWe actually at the moment still don't know if having some people vaccinated would "prevent cases among their contacts." The published results don't show that at all. What's published is only if the vaccines prevent the occurrence of the illness (as in "did somebody have symptoms"). Also: "Animal challenge data suggest that vaccinated animals may still be infected even if they don't experience symptoms." For more details (including the whole article from which is that citation) see my other comments here.
- civilized 6y agoUnfortunately there is some pessimism about whether a coronavirus vaccine is likely to provide "sterilizing immunity" which would prevent spread, as opposed to just reducing the severity of the disease. https://www.statnews.com/2020/05/22/the-world-needs-covid-19-vaccines-it-may-also-be-overestimating-their-power/ https://www.statnews.com/2020/05/22/the-world-needs-covid-19...
- ummonk 6y agoWould this mean we are having a bunch of asymptomatic reinfections resulting in retransmission? Surely we would have seen a lot of examples of this already with test and trace?
- ptaipale 6y agoI'm a complete layman here, but I would expect that the "prevent spread" is not binary, it's a spwetrum [0,1]. Thus, even if it does not completely prevent spread, if just a part, or even a smallish part, is prevented, that also helps others. (Same thing in mask discussion. Lots of people dismiss masks because they may not completely prevent an infection; that is stupid, because masks still decrease the probability of infection (and more importantly, spreading to others).
- devit 6y agoThe "absolute risk reduction" and NNT numbers seem pretty useless, since they are in a context where people are trying their best to avoid getting infected with isolation, masks, distancing, etc. Once the vaccine rolls out, people will return to previous habits and without the vaccine a large percentage of the population would be infected, so these numbers look completely different (i.e. absolute risk reduction of at least 45% from 50% to 0-5%, and NNT of something like 3-to-1 to 10-to-1).
- rwoerz 6y agoYou get 20,567 in each arm??? That's a thorough study. Hope they had enough plasters. SCNR
- zeku 6y agoArm in this context is a medical term referring to a study site or something like that. It's not literally someone's arm.
- neilwilson 6y agoIt's not primarily about eliminating symptomatic cases. It's about eliminating excessive fear. And fear kills economic activity.
- gorgoiler 6y agoIs the study continuously rolling / ongoing?
- Karrot_Kream 6y agoParticipants will continue to be monitored for the next 2 years. This just marks the point at which Pfizer can claim their vaccine to be more than 30% effective.
- virtuallynathan 6y agoThey will unfortunately vaccinate the placebo arm as soon as they get the EUA. At this point the study would be mostly unblinded, so far as I can tell, there will also be a much smaller, if any control group. “If our potential vaccine receives an EUA, we would propose amending the study protocol to create a process so that interested, eligible participants who received the placebo could ‘cross-over’ to the vaccine arm of the study,”
- patall 6y agoNote that it is 170 cases as defined in the study protocol. Which is not positive in a PCR test like you see in the media, it is positive in PCR while showing symptoms.
- jostmey 6y agoI just read that Pfizer reports its vaccine as 95% effective, even though pharmaceutical originally reported its vaccine as 90% effective. This new number matches Moderna's reported effectiveness reported yesterday. I don't know enough about how the reporting process works. To me, it appears that Pfizer will report whatever number sounds good, not the true number. I'm glad several states, like New York, want to review the clinical trial data independently of the FDA EDIT: I am getting serious downvotes for this comment! Whoops! I do not mean to suggest people should not take the vaccine, only that the optics of news presses look bad. I say this as someone who takes the Flu vaccine every year and elected for the HPV vaccine a few years ago
- GhostVII 6y agoThey got more data so they updated the number to 95%, if a member of the public doesn't understand that they are just being willfully ignorant.
- Rebelgecko 6y agoHow much more data did they get? For a trial that's been going on for months, it seems nonintuitive that 2 more days of data would move the needle so much
- gns24 6y agoWell with case counts in the US doubling roughly every two weeks, you would expect to see the number of cases among trial participants there doubling over that period.
- vermontdevil 6y ago“I don’t know enough about the reporting process” yet continues to come up with a theory based on nothing.
- jostmey 6y agoI added that sentence to make it clear that I am not an expert. I am highlighting how this appears to me. I was hoping that someone with experience working in clinical trials would chime in
- deleted 6y ago[deleted]
- biffstallion 6y agoWaiting for Biden/Harris to take credit for this.
- skocznymroczny 6y agoI don't really trust any kind of data coming from companies (or government for that matter). I will wait few years and see for myself if there are no side effects. I am surprised so many people are suddenly in full "believe the science" mode, especially when big pharma companies weren't exactly the most ethical players on the market in the past.
- mmachado95 6y agoI'm surprised you're so cynical to the point you don't trust anyone
- HarryHirsch 6y agoI'm not - the government's messaging throughout the whole pandemic has been "get back to work, peon". There is absolutely no reason to believe that the two vaccines aren't more of the same. You need to work with accurate priors.
- wbronitsky 6y agoI'm not sure how the government's messaging during the pandemic affects a private company, with global shareholders, claiming efficacy of a product whose results will be plain to see for all of those shareholders. You cannot lie about your products in an open market and be successful. Sure, we should be skeptical of the government line on the pandemic, but why should we be skeptical of a product that comes from a company whose product must work for them to make money? I think instead of letting our previous biases in one arena influence our current decision making in another, we should look at the evidence, make an independent decision, and then loop back on that when the evidence changes. Government bad != private company creates product that doesn't work
- HarryHirsch 6y agoThere is no reason to believe in long-term safety, neither is there reason to believe in long-term efficacy, the vaccine is too new for that to have any good data, meanwhile the manufacturers are indemnified to the hilt. Not that there's anything wrong with vaccine indemnification, when the product is proven safe and improves public health, as the vaccines on the markets all are, but this one was rushed through at unprecedented speed. And what's with the trust in the market to fix things? The 737-MAX crashes did not affect Boeing share price or Boeing management in any meaningful way, neither are safety problems with the new covid vaccines going to affect Pfizer or Moderna.
- ddp26 6y agoDoes this mean the vaccine has passed FDA Phase 3 trials? What comes next?
- kgwgk 6y agoEmergency Use Authorization when the FDA reviews the results. https://www.statnews.com/2020/11/17/pfizer-may-be-within-days-of-filing-emergency-authorization-request-for-covid-19-vaccine/ https://www.statnews.com/2020/11/17/pfizer-may-be-within-day...
- thdrdt 6y agoThere are already 2 known virus mutations: G614 and D514. In Italy new research suggests even a 3rd mutation might go around. And Denmark also had a mutation. Do those vaccines work on all mutations or are they like the common flu vaccines that must be adapted every year?
- mlyle 6y agoYes, at this time, all virus variants have the same spike structure where the vaccines and commonly produced antibody responses to vaccine/infection target. Oddly enough, the G614 mutation is moderately more vulnerable to neutralization. Once enough people are no longer susceptible/vaccinated, there may be considerably more selective pressure for the virus to mutate in ways that antibodies to past variants don't work. Whether we'll get variants that are virulent and bypass immunity is TBD. The spike protein is functional; changes to it that bypass immunity likely reduce function.
- Kuraj 6y agoIs it correct that once enough people get vaccinated, even if we don't eradicate the virus, it will have to mutate into something milder in order to still effectively spread?
- feanaro 6y agoIt is not a given that it will be milder, just estimated to be more likely once everything is taken into account. As an example of why, the comment you are responding to mentioned the spike being functional (it is used by the virus for cell entry) and it is also targeted by our antibodies. So, for the virus to evade antibodies, it would have to change the spike enough so that antibodies don't detect it anymore. But, by changing it would likely lose some of its current efficacy.
- CapriciousCptl 6y agoThere's some nuance to this. The current most common strain is theoretically the most genetically fit strain. Wide use of vaccines targeting conserved regions of the spike protein almost certainly would result in less genetically fit virus progeny becoming more common by simple selection. But, there's no predicting the virulence of the the less genetically fit strains that will pop up. ie) very deadly viruses aren't necessarily very genetically fit. The short of it is, the resultant strains will probably be less transmissible (the "R" number will decrease), but it's hard to predict their virulence/serverity. I think consensus is we don't know for sure, but there's reason to be hopeful. SARS-CoV-2 probably won't evolve as fast as the flu, which undergoes a "sexual-like" evolution process called "re-assortment." On the other hand, CoV-2 has "re-combination," which gives similar results, and it does have zoonotic hosts.
- SoSoRoCoCo 6y agoI'm confused, who actually made the vaccine? I read that BionTech created it and Pfizer is handling logistics, approval, and distribution in the US. But I keep seeing it as "Pfizer's vaccine"?
- mandelbrotwurst 6y agoI share your understanding of which companies did what. You're probably reading U.S. media sources. Wouldn't surprise me at all if BionTech have similar partnerships with large pharma companies in other countries, where the media there similarly claim it for their national champion.
- lultimouomo 6y agoIt is known as the Pfizer/BioNTech vaccine in europe as well; Pfizer did not just handle logistics but the trials as well, which are a huge part of the effort.
- mandelbrotwurst 6y agoOh, fair enough!
- LEARAX 6y agoIt sounds like BioNTech did all the development work on the vaccine, but Pfizer funded the actual creation of the vaccine and runs the trials/logistics/finances/business stuff (considering how temperature-sensitive this is, logistics have to be fairly painful). Both should probably be credited (as they are in this article).
- mandelbrotwurst 6y agoYou're right. I was being overly cynical and dismissive towards Pfizer's role after seeing many headlines crediting ONLY Pfizer.
- deleted 6y ago[deleted]
- stevecalifornia 6y agoA delightful moral dilemma: There is concern that the vaccine stops you from developing Covid symptoms but not from becoming asymptomatic. If it turns out that the vaccines do not prevent you from being asymptomatic (you can still spread Covid), what is your obligation to wear a mask have continued lockdowns to protect people who refuse to get the vaccine?
- peter422 6y agoYou still need to wear a mask, but once vaccination rates are high enough the pandemic will roughly end and people as a whole can stop wearing them. Also remember that by vaccinating the highest risk patients first we can make big impacts in the death toll without necessarily stopping the spread of cases.
- deleted 6y ago[deleted]
- notRobot 6y agoI don't see any dilemma. Doing a simple thing can save lives. Why wouldn't you?
- deleted 6y ago[deleted]
- relativeadv 6y agoI'm not obligated to do many things. I do however wear a mask because it is the right thing to do. This isn't a moral dilemma.
- fairity 6y agoI believe GP's hypothetical assumes that everyone has an opportunity to get vaccinated, and all those who remain susceptible to the virus refused to get vaccinated for selfish reasons. If society continues to coddle anti-vaxers, it reinforces a positive incentive for selfish behavior, which in turn creates a negative drag on overall well-being. At a certain point, society shouldn't allow the selfish acts of small group of individuals undermine the well-being of society at large. Obviously, there would need to be ample warning and a concerted effort to educate everyone on consequences. Once these requirements are met in this hypothetical, I believe the moral thing to do is to stop wearing masks and stop social distancing. That said, this is an idealized hypothetical. In reality, there will be many people who can't get vaccinated for reasons that are not selfish. In this case, there is still a moral dilemma, but I'm unsure on how I'd approach it. Surely, asking 200 million people to wear masks for another year to save 1 life isn't worth it. The question is where to draw the line.
- andred14 6y agoblah blah blah NO THANK YOU
- dang 6y agoCould you please stop posting unsubstantive comments to Hacker News? We're trying for something different here. https://news.ycombinator.com/newsguidelines.html https://news.ycombinator.com/newsguidelines.html
- ummonk 6y agoDo we know if any of the cases on the treatment side of the study led to hospitalizations? (I.e. were the cases as mild as the average control group case, or did we have a selection effect where the cases that did turn up in the treatment group were more severe?)
- hannob 6y ago"Of the 10 cases of severe Covid-19, nine were in the placebo group, an important finding which suggests the vaccine prevents not only mild cases, but the type of serious disease that leads patients to die or be hospitalized." https://www.statnews.com/2020/11/18/pfizer-biontech-covid19-vaccine-fda-data/ https://www.statnews.com/2020/11/18/pfizer-biontech-covid19-...
- usrusr 6y agoSo the distribution amongst vaccinated group cases seems to be roughly the same as on the control group. In my armchair viroligy ponderings I have come to the conclusion that this is the best possible outcome because both directions of possible distribution shifts could be bad news: if all detected vaccinated cases would be hard cases it would indicate that the vaccine has much lower efficacy than stated with those that require the hardest to be saved by a vaccine, whereas an overrepresentation of weak cases would suggest that much more weak cases get through, that the vaccine would not prevent infection very much but only keep an infection from becoming a heavy case (weak cases are very likely to remain undetected in both the vaccinated group and in the control group). A downshift in severity would be just fine for the vaccinated, but with a virus like SARS-COV-2 that is very good at asymptomatic spread it would not contribute much to herd immunity, increasing risk for the non-vaccinated (because the lucky ones would drop all precautions.
- ummonk 6y agoAwesome, thanks! This is really great news.
- notatoad 6y agoif the vaccine is ~90% effective, wouldn't we expect that for any ten random cases in the trial, 9 would be in the placebo group? i don't see how that rate implies anything about the severity of the infection
- hikerclimber 6y agohope virus mutates so that masks don't work since we don't have any mask in existence which can protect against it.
- hikerclimber 6y agohopefully the virus mutates so lots of people die.
- hikerclimber 6y agohopefully the virus kills the most number of people in the U.S. by mutating so no masks work and millions of people in the U.S. die.